| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Centene (NYSE:CNC) over the last quarter vary from bullish to bearish, as provided by 24 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 16 | 1 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 2 | 2 | 7 | 1 | 0 |
| 3M Ago | 0 | 1 | 6 | 0 | 0 |
Analysts have set 12-month price targets for Centene, revealing an average target of $38.67, a high estimate of $65.00, and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 34.88%.
The standing of Centene among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ryan MacDonald | Truist Securities | Raises | Buy | $39.00 | $35.00 |
| Andrew Mok | Barclays | Raises | Equal-Weight | $35.00 | $33.00 |
| Lance Wilkes | Bernstein | Lowers | Outperform | $36.00 | $40.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $33.00 | $45.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $38.00 | $38.00 |
| Ricky Goldwasser | Morgan Stanley | Lowers | Equal-Weight | $28.00 | $33.00 |
| John Stansel | JP Morgan | Lowers | Neutral | $30.00 | $48.00 |
| A.J. Rice | UBS | Lowers | Neutral | $31.00 | $45.00 |
| Ryan MacDonald | Truist Securities | Lowers | Buy | $35.00 | $42.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $43.00 | $51.00 |
| Sarah James | Cantor Fitzgerald | Lowers | Neutral | $38.00 | $65.00 |
| Michael Ha | Baird | Lowers | Neutral | $28.00 | $68.00 |
| Stephen Baxter | Wells Fargo | Lowers | Equal-Weight | $30.00 | $72.00 |
| Ryan Langston | TD Cowen | Lowers | Hold | $33.00 | $73.00 |
| Ryan MacDonald | Truist Securities | Lowers | Buy | $42.00 | $84.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Underperform | $30.00 | $52.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $51.00 | $85.00 |
| Ann Hynes | Mizuho | Lowers | Neutral | $40.00 | $71.00 |
| Ricky Goldwasser | Morgan Stanley | Lowers | Equal-Weight | $33.00 | $70.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $45.00 | $65.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Neutral | $52.00 | $65.00 |
| Sarah James | Cantor Fitzgerald | Lowers | Overweight | $65.00 | $90.00 |
| A.J. Rice | UBS | Lowers | Neutral | $45.00 | $80.00 |
| John Stansel | JP Morgan | Lowers | Neutral | $48.00 | $75.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Centene's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Centene analyst ratings.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Centene showcased positive performance, achieving a revenue growth rate of 22.36% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Centene's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.29%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Centene's debt-to-equity ratio is below the industry average at 0.64, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CNC
